Cocrystal Pharma Reports Phase 1 Results with Oral, Broad-Acting Antiviral Drug CDI-988 for Prophylaxis and Treatment of Norovirus, Coronaviruses and Other Viral Infections

Core Insights - Cocrystal Pharma, Inc. has reported positive safety and tolerability results for its oral protease inhibitor CDI-988, which is being developed as a treatment for norovirus and coronavirus infections [1][2][3] - The company plans to conduct an additional cohort study with a higher dose of 1,200 mg and a shorter treatment duration of five days to further evaluate CDI-988's safety and pharmacokinetics [1][3] Company Overview - Cocrystal Pharma is a clinical-stage biotechnology company focused on discovering and developing novel antiviral therapeutics targeting the replication processes of various viruses, including noroviruses and coronaviruses [8] - The company utilizes a proprietary structure-based drug discovery platform to develop its antiviral agents, aiming to create first- and best-in-class therapies [6][8] Industry Context - Norovirus outbreaks are increasing in the U.S. and on cruise ships, with nearly 900 passengers affected in December 2024 alone, highlighting a significant unmet medical need for effective antiviral treatments [2][5] - According to the CDC, noroviruses cause an estimated 21 million cases of acute gastroenteritis annually in the U.S., leading to significant healthcare costs and hospitalizations [5]